RT Journal Article
T1 A national longitudinal study evaluating the activity of cefditoren and other antibiotics against non-susceptible Streptococcus pneumoniae strains during the period 2004–20 in Spain
A1 Sempere, Julio
A1 González-Camacho, Fernando
A1 Domenech Lucas, Miriam
A1 Llamosí, Mirella
A1 Del Río, Idoia
A1 López-Ruiz, Beatriz
A1 Gimeno, Mercedes
A1 Coronel, Pilar
A1 Yuste, José
AB BackgroundSurveillance studies including antibiotic resistance and evolution of pneumococcal serotypes are critical to evaluate the susceptibility of commonly used antibiotics and the contribution of conjugate vaccines against resistant strains.ObjectivesTo determine the susceptibility of clinical isolates of Streptococcus pneumoniae with reduced susceptibility to penicillin to a panel of antibiotics during the period 2004–20 and characterize the impact of pneumococcal conjugate vaccines in the evolution of resistant serotypes.MethodsWe selected 3017 clinical isolates in order to determine the minimal inhibitory concentration to penicillin, amoxicillin, cefotaxime, erythromycin, levofloxacin and oral cephalosporins, including cefditoren, cefixime and cefpodoxime.ResultsThe antibiotics with the lowest proportion of resistant strains from 2004 to 2020 were cefditoren (<0.4%), followed by cefotaxime (<5%), penicillin (<6.5%) and levofloxacin (<7%). Among oral cephalosporins, cefixime was the cephalosporin with the highest MIC90 (32 mg/L) and MIC50 (8–16 mg/L) throughout the study, followed by cefpodoxime with highest values of MIC90 (4 mg/L) and MIC50 (2 mg/L) for the majority of the study period. In contrast, cefditoren was the cephalosporin with the lowest MIC90 (1 mg/L) and MIC50 (0.25–0.5 mg/L).ConclusionsCefditoren was the antibiotic with the highest proportion of susceptible strains. Hence, more than 80% of the clinical strains were susceptible to cefditoren throughout the period 2004–20. The proportion of resistant isolates to cefditoren and cefotaxime was scarce, being less than 0.4% for cefditoren and lower than 5% for cefotaxime, despite the increased rates of serotypes not covered by the 13-valent pneumococcal conjugate vaccine.
PB Oxford University Press
SN 0305-7453
YR 2022
FD 2022
LK https://hdl.handle.net/20.500.14352/87401
UL https://hdl.handle.net/20.500.14352/87401
LA eng
NO Julio Sempere, Fernando González-Camacho, Mirian Domenech, Mirella Llamosí, Idoia Del Río, Beatriz López-Ruiz, Mercedes Gimeno, Pilar Coronel, Jose Yuste, A national longitudinal study evaluating the activity of cefditoren and other antibiotics against non-susceptible Streptococcus pneumoniae strains during the period 2004–20 in Spain, Journal of Antimicrobial Chemotherapy, Volume 77, Issue 4, April 2022, Pages 1045–1051, https://doi.org/10.1093/jac/dkab482
NO Ministerio de Economía, Industria y Competitividad (España)
NO Ministerio de Ciencia e Innovación (España)
NO Meiji Pharma Spain
DS Docta Complutense
RD 17 abr 2025